Panbela Therapeutics

Panbela Therapeutics is a clinical-stage biopharmaceutical company based in the United States that focuses on developing disruptive therapeutics for urgent unmet medical needs, with a current emphasis on treating patients with pancreatic cancer. The company's pipeline utilizes polyamine metabolic inhibitor (PMI) drug targeting strategies to address therapeutic areas of high unmet medical need, including oncology and orphan diseases.